{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"42.1"}]}],"title":"72 hours - Very good [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"39.5"}]}],"title":"72 hours - Good [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1"},{"groupId":"OG001","value":"18.4"}]}],"title":"72 hours - Fair [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"0.0"}]}],"title":"72 hours - Poor [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"72 hours - Very poor [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9"},{"groupId":"OG001","value":"59.0"}]}],"title":"7 days - Very good [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9"},{"groupId":"OG001","value":"38.5"}]}],"title":"7 days - Good [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5"},{"groupId":"OG001","value":"2.6"}]}],"title":"7 days - Fair [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"0.0"}]}],"title":"7 days - Poor [N=58, 39]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"7 days - Very poor [N=58, 39]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"The study physician made a global assessment of the patient's response to treatment using a 5-point Likert scale: very good, good, fair, poor or very poor.\n\nThe physician completed the physician's global assessment of response to treatment without viewing any of the patient's assessments.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","groups":[{"description":"Participants who received canakinumab 150 mg in the core study and who were re-treated with canakinumab 150 mg for new flares during the overall 72 weeks. Data are reported for the last post-baseline flare for participants in this arm.","id":"OG000","title":"Re-treated With Canakinumab 150 mg"},{"description":"Participants who received triamcinolone acetonide (triam) 40 mg in the core study and who were switched to canakinumab 150 mg for treatment of new flares in extension study 2. Data are reported for the first post-baseline flare treated with canakinumab.","id":"OG001","title":"Triam Switched to Canakinumab"}],"paramType":"NUMBER","populationDescription":"Modified Analysis Set (MAS) consisting of all FAS patients who were either re-treated or switched to canakinumab during the 72 weeks. At each timepoint only patients with a value at both baseline flare and the new flare are included.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose and 7 days post dose for the last post-baseline flare for the canakinumab re-treated arm and for the first post-baseline flare treated with canakinumab in the triamcinolone acetonide arm during the overall 72 weeks.","title":"Physician's Global Assessment of Response to Treatment for Participants Re-treated or Switched to Canakinumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}